# Cardiac glycosides (digoxin)

Drug · id `cardio:cardiac-glycosides-digoxin` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Cardiac glycosides; Cardiac glycoside; Digitalis glycosides; Cardiotonic steroids

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems; Heart failure  

## In plain language

Cardiac glycosides, also called digitalis glycosides, are a group of medicines that act on the heart muscle. MeSH says they increase the force of heart contraction but are very toxic at larger doses. Digoxin (Lanoxin) is the one medicine of this group with a page in this atlas, and that page is filed under this class. This is the class page.

## Technical summary

Class page. MeSH descriptor D002301 (Cardiac Glycosides) is an exact match; its entry terms include Cardiac Glycoside and Cardiotonic Steroid (read 2026-11-18, hash only). The scope note says plants they come from have long been used in congestive heart failure, that the compounds increase the force of cardiac contraction, and that the mechanism usually involves inhibition of the sodium-potassium ATPase. The Lanoxin label read (Advanz Pharma (US) Corp., NDA020405, effective 2024-12-05) calls Lanoxin a cardiac glycoside and one of the cardiac (or digitalis) glycosides, and lists, for adults, mild to moderate heart failure and control of resting ventricular rate in chronic atrial fibrillation among its indications. RxClass lists Cardiac Glycoside as the established pharmacologic class of digoxin on US drug labels; digoxin is filed under this page on that evidence. MeSH also places cardiac glycosides among the agents that strengthen the heart; a separate class page covers that wider group. No trial result and no dose is recorded.

## Connected pages

- Files under this front: Medicines (`cardio:front-medicines`)
- MeSH: plants these compounds come from have long been used in heart failure: Heart failure (`cardio:heart-failure`)
- A US digoxin label lists control of resting ventricular rate in adults with chronic atrial fibrillation: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- MeSH names cardiac glycosides among cardiotonic agents: Inotropes and vasopressors (`cardio:inotropes-and-vasopressors`)
- Has subtype: Digoxin (`cardio:digoxin`)

## Provenance

Content hash: 032782024bf23428ff8ebe55b0339069cd58c510b57f2c6713b5ccb34233b08b
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
